drugset
drugset / Trial / NCT00277290

Study of XL999 in Patients With Previously Treated Ovarian Cancer

NCT00277290 ↗

Phase 2 Terminated 24 enrolled Symphony Evolution, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This clinical trial is being conducted at multiple sites to evaluate the activity, safety, and tolerability of XL999 when given weekly to patients with ovarian cancer that has previously been treated with platinum-based chemotherapy. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Timeline

Start
2006-01
Primary completion
2006-11
Completion
2006-11

Outcome

Outcome not reported

Stopped: “Study was terminated due to cardiac toxicities in the subjects”

Drugs

EvaluationDrugModalityDoseRoute
Subject XL999 Small molecule 2.4 mg/kg Intravenous

Indications

ovarian cancer